Medication reference
Calcium gluconate
Monograph awaiting updateThis monograph will be updated in the future.
Historical source. Current clinical review is incomplete. This monograph will be updated in the future.
Calcium Gluconate (ca Gluc) (opens in a new tab)Original source URL: https://globalrph.com/dilution/calcium-gluconate-ca-gluc/ | Retrieved 2026-11-04
Source dates, location and integrity
This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.
- Original source URL
- https://globalrph.com/dilution/calcium-gluconate-ca-gluc/ (opens in a new tab)
- Source date
- Not established in the retrieved source
- Retrieved
- 2026-11-04T19:44:37.133564+00:00
- Source location
- div.post-content
- Packaged content SHA-256
- 035c2d601b03d53c1a2a58ee313baca048661a0ae6284867db5ac1a4f75b63c4
- Original response SHA-256
- d7b76762eb9a00127c03e56966fc1b13edbe7d4f6d15940620cf46b7e2f04470
- Source body SHA-256
- 9c4b5609969062febfee0b33af4f32784e795e3d2d378c20d399b4579a72a3dc
CALCIUM GLUCONATE |
||||||||||||||
| The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. | ||||||||||||||
Usual Diluents |
||||||||||||||
| D5W, NS Calcium chloride link | ||||||||||||||
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] |
||||||||||||||
| [1 to 4 grams] [50 - 100 ml] [See comments]*
Alternatively: *Dilutions assume peripheral line is used as well as D5W as the primary diluent (see comment section below - calculation of solution osmolarity). ^Actual infusion times should be based on serial calcium levels, severity of the deficit, current phosphate level (possible metastatic calcification), and the clinical presentation of the patient (acute versus chronic; symptoms present; etc.). Treatment of emergent (acute symptomatic) patient. 1. [The injection should be halted if the patient complains of any discomfort; it may be resumed when symptoms disappear. Following injection, the patient should remain recumbent for a short time. 2] Calcium Gluconate: Maximum rate: 1.5 mL/minute = 0.7 meq/minute. 3 See monograph for general dosing. Smaller volumes may be used in patients with a central line. Actual infusion rates should be based on the severity of the deficit. In non-emergent cases (asymptomatic patients), oral therapy is preferred. -Serum calcium levels should be measured every 2 to 6 hours to guide continued therapy. If the patient has a low serum albumin level, ionized calcium should be monitored. -The following patients need continuous ECG monitoring during calcium infusions: (1) Patient's with cardiac arrhythmias or (2) Patients receiving digoxin therapy. Continuous infusion: Initially multiply ( 0.5 x Wt (kg) X 24 ) / 93 mg = number of grams of calcium gluconate needed. Add calculated amount to 500 to 1000 ml D5W or NS. A continuous infusion may be used in symptomatic patients with hypocalcemia. Infusion rate: 0.3 to 2 mg/kg/hr based on elemental calcium. The actual rate should be based on serial plasma calcium levels. |
||||||||||||||
Comments / Stability / Miscellaneous |
||||||||||||||
| 1 gram= 4.65 meq (93 mg) 10 ml.
"Hypocalcemia is defined as a serum calcium concentration <8.5 mg/dL (or ionized calcium <4.2 mg/dL). Symptoms of hypocalcemia usually occur when ionized levels fall to <2.5 mg/dL. Symptoms include paresthesias of the extremities and face, followed by muscle cramps, carpopedal spasm, stridor, tetany, and seizures. Hypocalcemic patients show hyperreflexia and positive Chvostek and Trousseau signs. Cardiac effects include decreased myocardial contractility and heart failure." [Source].
Osmolarity calculations:Return to article top source: https://globalrph.com/medcalcs/osmolarity-calculator-extremely-powerful-tool/ Osmolarity calculations: source: https://globalrph.com/medcalcs/osmolarity-calculator-extremely-powerful-tool/ Maximum IV rate: 1.5 ml/min or approximately 1 gram/ 7 minutes. Too rapid injection may decrease blood pressure or cause cardiac syncope. Calcium administration: (Onset: rapid Duration: 30min to 2 hours. ). Recommended only in cases of hyperkalemia, hypocalcemia, or calcium antagonist blockade. -------------------------------------------------------------------------------- Treatment of hypocalcemia: Acute hypocalcemic tetany (unless induced by alkalosis): give 1 gram calcium gluconate IV over 5 - 15 minutes. After 1-2 hours may be necessary to repeat dose or add 2-3 grams calcium gluconate to 250-500ml and infuse over 12-24hours. ----Alternatively---- Asymptomatic patient: 1 gram calcium gluconate IV q6-12h with careful monitoring of Ca++ levels. Monitoring: during intensive therapy, monitor calcium levels at least twice daily. -------------------------------------------------------------------------------- Differentiation of hypoparathyroidism vs Vitamin D deficiency: Drug Monograph - Calcium gluconateDRUG DESCRIPTION INDICATIONS Precautions To avoid undesirable reactions that may follow rapid intravenous administration of calcium gluconate, the drug should be given slowly, e.g., approximately 1.5 mL over a period of one minute. When injected intravenously, calcium gulconate should be injected through a small needle into a large vein in order to avoid too rapid an increase in serum calcium and extravasation of calcium solution into the surrounding tissue with resultant necrosis. Rapid injection of calcium gluconate may cause vasodilation, decreased blood pressure, bardycardia, cardiac arrhythmias, syncope and cardiac arrest. Because of the danger involved in simultaneous use of calcium salts and drugs of the digitalis group, a digitalized patient should not receive an intravenous injection of a calcium compound unless indications are clearly defined. Drug Interactions Calcium complexes tetracycline antibiotics rendering them inactive. The two drugs should not be given at the same time orally nor should they be mixed for parenteral administration. Calcium gluconate injection has been reported to be incompatible with intravenous solutions containing various drugs. Published data are too varied and/or limited to permit generalizations, and specialized reference should be consulted for specific information. Adverse Reactions Rapid intravenous injection of calcium salts may cause vasodilation, decreased blood pressure, bardycardia, cardiac arrhythmias, syncope and cardiac arrest. Use in digitalized patients may precipitate arrhythmias. Local necrosis and abscess formation may occur with intramuscular injection. DOSAGE AND ADMINISTRATION Usual Dosage Children: 200-500 mg (2-5 mL) Infants: not more than 200 mg (not more than 2 mL) HOW SUPPLIED NDC 0517-3910-25 10% 10 mL Single Dose Vials packed in boxes of 25 Supersaturated solutions are prone to precipitation. NOTE: If crystallization has occurred, warming in a 60°C water bath for 15-30 minutes with occasional shaking, may dissolve the precipitate. Cool to body temperature before use. The injection must be clear at the time of use. Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit. No preservative added. Unused portion of vial should be discarded. Use only if solution is clear and seal intact. Store at controlled room temperature 15º- 30ºC (59º- 86ºF) (See USP). References: Return to article top[1 ] 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-Threatening Electrolyte Abnormalities. Circulation. 2005;112:IV-121-IV-125. Accessed - revisited: 05/01/11. [2 ] CALCIUM CHLORIDE injection, solution (10% Calcium Chloride) [Hospira, Inc.] Hospira, Inc., Lake Forest, IL 60045 USA. Revised: November, [3 ] CALCIUM GLUCONATE injection, solution (10% CALCIUM GLUCONATE). APP Pharmaceuticals, LLC. Schaumburg, IL 60173. Revised: [4 ] Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:245-6. |
||||||||||||||
Product identifiers and clinical review status
This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
- Clinically reviewed, individually identified statements with two exact source mappings
- Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
- Renal-function methods and dialysis/CRRT modality review where applicable
- Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation
Supplemental historical fields
Restored-data provenance and review notes
Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.
Current review annotations for historical renal, dialysis, mechanism, and product fields
Separate renal reference: Open Renal Dosing Master (opens in a new tab)- Renal
- Status
- not_locally_normalized
- Original classification
- monitor_or_titrate
- Entries
- General note
- Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
- Dialysis
- Status
- no_local_structured_regimen
- Entries
- General note
- Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
- Mechanisms
- Source kind
- first_look
- Local pointer
- /mechanism
- Original level
- drug_specific
- Provenance classification
- historical_drug_specific_uncorroborated
- Label derived verified
- false
- Independently corroborated
- false
- Exact label section
- Not recorded
- Original source note
- Not recorded
- Review status
- historical_unverified
- Note
- Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
- Future update
- Status
- pending_review
- Message
- This monograph will be updated in the future as current exact-product and claim-level review is completed.
- Source unavailable
- false
- Reason
- The historical content is restored; comprehensive contemporary verification remains incomplete.
Historical first look: uses, mechanism, dosing context, and administration
Recovered v5.1 source content; historical, awaiting current review.
- Id
- calcium-gluconate
Source ID
H51-3A305A9ED9CE3227633E45AA - Generic name
- Calcium gluconate
Source ID
H51-A6B682C9FBEBF4F4D16AF656 - Class
- Electrolytes and fluids
Source ID
H51-528E3CE6EB4AB0BC759A5E92 - Subclass
- Calcium replacement
Source ID
H51-B336C84EEC81AB6B7E51148F - Primary uses
- Hypocalcemia
Source ID
H51-15A7DA97D9610B798D65C067 - Hyperkalemia with ECG changes
Source ID
H51-363938626FC01E70EA255CC0 - Calcium-channel blocker toxicity
Source ID
H51-AD95CF9175CDBDE69444EB7B
- Hypocalcemia
- Mechanism
- Supplies ionized calcium for membrane excitability, contraction, coagulation, and signaling.
Source ID
H51-FD4E25B94EBF047770CDD872 - Mechanism level
- drug_specific
Source ID
H51-11D9BA5EE15FFDA5C878D82F - Basic dosing orientation
- Adult | Existing preparation record; use current package insert for indication-specific selection | Common dose 1 to 2 g of 10% solution | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric and neonatal | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion
Source ID
H51-71BE40FEB968F8B181962237 - Administration orientation
- Infuse over 10 to 60 minutes depending on urgency and dose; Slow monitored administration; 100 mg/mL or diluted; Usually over approximately 10 minutes while perfusing
Source ID
H51-7CAD93A8254D18DAE9B3DB2D - Renal and population orientation
- Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply.
Source ID
H51-8B14B55F017469153989EA30 - Key safety orientation
- Do not mix with bicarbonate or phosphate solutions.
Source ID
H51-3580864E16FB0D14109AB853 - Extravasation can still cause injury.
Source ID
H51-F3AB8EA0D75BF5FFD05A7C98 - Use caution with digoxin toxicity.
Source ID
H51-1C61A1C1081F29FEBA10FF3F
- Do not mix with bicarbonate or phosphate solutions.
- Coverage path
- structured_local_snapshot
Source ID
H51-BA42AF6917DF4D3E9059AA57 - Coverage path label
- Structured GlobalRPh route snapshot
Source ID
H51-0E4A17169D7FAE3B168DCF4E - Legacy title
- Calcium gluconate
Source ID
H51-6E0C550FCD57FAED7806CDDB - Review note
- First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
Source ID
H51-0579C62220ACC80BAB01ECC7 - Search text
- Calcium gluconate Electrolytes and fluids Calcium replacement Hypocalcemia Hyperkalemia with ECG changes Calcium-channel blocker toxicity Supplies ionized calcium for membrane excitability, contraction, coagulation, and signaling. Adult | Existing preparation record; use current package insert for indication-specific selection | Common dose 1 to 2 g of 10% solution | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric and neonatal | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion Infuse over 10 to 60 minutes depending on urgency and dose; Slow monitored administration; 100 mg/mL or diluted; Usually over approximately 10 minutes while perfusing Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply. Do not mix with bicarbonate or phosphate solutions. Extravasation can still cause injury. Use caution with digoxin toxicity. Structured GlobalRPh route snapshot
Source ID
H51-A96D5AA933DB577CC769F22B - Official search url
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Calcium+gluconate (opens in a new tab)
Source ID
H51-D2A988BCE82934A449055C13 - Official access mode
- search
Source ID
H51-E65AF12ADC139FCC63FFEC5B - Official access url
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Calcium+gluconate (opens in a new tab)
Source ID
H51-9AFA308CE86D023F004BFCA8 - Official search query
- Calcium gluconate
Source ID
H51-4A3C37830387524DA5AA3B0B - Official access reason
- A source-backed DailyMed search is available; select and confirm the exact IV product.
Source ID
H51-2E139A751E58F87716D26956
No separate structured rows were bundled for continuous infusion, dialysis, CRRT. Historical article content and source links may cover these topics.
Historical dilution and intermittent infusion preparation
Recovered v5.1 source content; historical, awaiting current review.
| Population | Amount | Reconstitution | Diluent | Final volume | Concentration | Rate | Stability | Notes |
|---|---|---|---|---|---|---|---|---|
Source IDH51-752B67A443626F5C1F2893D0Source IDH51-FB053CE2D2711FD3DE2CE205 | Common dose 1 to 2 g of 10% solutionSource IDH51-889B5CDD7C4D4F6A4263BC46 | Usually supplied as 100 mg/mL solution.Source IDH51-89C81ADFD16C45A2CB4B065E | NS or D5WSource IDH51-AFEDE88CC768A0DA6262B435 | 50 to 100 mL for routine replacementSource IDH51-DC3BF63EB795AD688A077E37 | Commonly 10 to 20 mg/mLSource IDH51-68447324E43F8A031AE4CCAC | Infuse over 10 to 60 minutes depending on urgency and doseSource IDH51-B5CFE20F3FAD5BB0F023D13F | Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.Source IDH51-E6D2F4B78564B93B9F6CCA75 | For emergent membrane stabilization, a slow injection/short infusion may be used with ECG monitoring.Source IDH51-B30A5E439AAF55D99E33A849 |
Source IDH51-1B5C940C0267389EC03299AESource IDH51-2C20C18B2EA9D6F0ED2BCFC1 | Weight-based doseSource IDH51-CB53A0DEE0224B976AC7DE3D | Use pharmacy-prepared dilution.Source IDH51-199D2A8CB4EFB145E7527DC7 | Compatible fluidSource IDH51-95DBA33F8765BE5B215940D1 | Weight-appropriate volumeSource IDH51-6FEA4EADA8DCB1B5C5BB1663 | Protocol-specificSource IDH51-1498FD4AB0548478C21C60C2 | Slow monitored administrationSource IDH51-BE0E5485E342FF715917DB89 | Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.Source IDH51-83D2E3C56E644D009AC1A403 |
Historical IV-push guidance
Recovered v5.1 source content; historical, awaiting current review.
| Population | Dose scope | Concentration | Rate | Status | Notes |
|---|---|---|---|---|---|
Source IDH51-56211A897F6175595A2394F0Source IDH51-A2AB302526AE79C33C1EAC44 | Commonly 1 g of 10% solutionSource IDH51-684F93347BD818D8D4BAE993 | 100 mg/mL or dilutedSource IDH51-E9CABD6F8284690C76507FB1 | Usually over approximately 10 minutes while perfusingSource IDH51-86FCB0FDFB87FDE1A94BFA2C | Slow IV injection/short infusion; not a rapid pushSource IDH51-ED6EB375EA8FD96866C8005B | Confirm line patency and monitor ECG.Source IDH51-9C1BD6D1338553106622EE8E |
Historical indication and population dosing
Recovered tables and source-separated snapshots; full clinical revalidation remains pending.
Existing dose and route snapshots
| Route | Population | Indication | Dose | Interval | Duration | Administration | Source level | Notes |
|---|---|---|---|---|---|---|---|---|
Source IDH51-D16D18944A0473283DF011CFSource IDH51-D226F3C585313B94337057B6 | AdultSource IDH51-BFEFDA5E51F413357EBB18E5 | Existing preparation record; use current package insert for indication-specific selectionSource IDH51-2A5FA07D25FD68D74C553FF8 | Common dose 1 to 2 g of 10% solutionSource IDH51-9BBB03B67199EF800FEEDA77 | Not normalized in the preparation recordSource IDH51-FFD5CA9FDF7CB88D372F5EF7 | See current package insert and professional guidanceSource IDH51-111D0032481D85C4454AD5F1 | Infuse over 10 to 60 minutes depending on urgency and doseSource IDH51-B23C10D340A46A0C808346DE | Existing GlobalRPh structured preparation snapshotSource IDH51-DAAC23FBBB8BB4D5B335499C | For emergent membrane stabilization, a slow injection/short infusion may be used with ECG monitoring.Source IDH51-AED54F0BCCD41BF77CE46248 |
Source IDH51-39322B30B56D14E3B877CA6DSource IDH51-33BB04B913CCB4625C524181 | Pediatric and neonatalSource IDH51-4DD2ABE38F2AD2F2E87FAA03 | Existing preparation record; use current package insert for indication-specific selectionSource IDH51-12903A53641A5154ABB3676C | Weight-based doseSource IDH51-50F303815513C856A3D62CF6 | Not normalized in the preparation recordSource IDH51-7F50993576AC5C73501BACD9 | See current package insert and professional guidanceSource IDH51-594CD14D75B68A158F1B1D35 | Slow monitored administrationSource IDH51-D07048378CFD245F8B8AC0F6 | Existing GlobalRPh structured preparation snapshotSource IDH51-A7C53403A8D3348C0C1AFF9C | |
Source IDH51-8DD153F9710F0F5459BBDBAFSource IDH51-C5C9E73A4CDA4DA1BD3F3626 | Adult emergencySource IDH51-69EBB4D296621642E518C983 | Commonly 1 g of 10% solutionSource IDH51-D00ABF74FC2E18CB59FEAAB3 | Commonly 1 g of 10% solutionSource IDH51-BB1F4EBD3654D4E3C0C3FB8F | Patient- and indication-specificSource IDH51-10CA5B94042DA1C4B338CF9A | See current package insertSource IDH51-ED5872DAF1571A648B7BFA14 | Usually over approximately 10 minutes while perfusingSource IDH51-19319F212AF56EBD3E01C899 | Existing GlobalRPh IV push snapshotSource IDH51-1A159382BF5DF9FA22A986DA | Slow IV injection/short infusion; not a rapid push Confirm line patency and monitor ECG.Source IDH51-34433989BB37032D64630286 |
Historical renal-function guidance
Recovered v5.1 source content; historical, awaiting current review.
Separate renal reference: Open Renal Dosing Master (opens in a new tab)- Classification
- monitor_or_titrate
Source ID
H51-80295CBD8DB0B71177C9C1F4 - Summary
- Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply.
Source ID
H51-E0757F1AD49037951B277605 - Method note
- Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
Source ID
H51-145E2C382E1240CD559E5657
Historical Common IV uses
Recovered v5.1 source content; historical, awaiting current review.
- Hypocalcemia
Source ID
H51-77AE02271CB27C17B26F7636 - Hyperkalemia with ECG changes
Source ID
H51-A011BABB2CDCC47F184A063C - Calcium-channel blocker toxicity
Source ID
H51-D80D84BB2E4A714260201937
Historical Warnings and safeguards
Recovered v5.1 source content; historical, awaiting current review.
- Do not mix with bicarbonate or phosphate solutions.
Source ID
H51-C6F97FB0A8B425F614A5ACB2 - Extravasation can still cause injury.
Source ID
H51-7DF0509F448ADB346365032C - Use caution with digoxin toxicity.
Source ID
H51-33DF67AB9D27C846EC1E2E4E
Historical Monitoring
Recovered v5.1 source content; historical, awaiting current review.
- ECG during urgent use
Source ID
H51-CC776726D281464802774F75 - Ionized calcium
Source ID
H51-0391EC0E76F629FAB5B255B2 - IV site
Source ID
H51-78E8C82F667891C85988356C
Other recovered source fields and original editorial metadata
Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.
Catalog source fields
Id
calcium-gluconateSource ID
H51-0B77ECC74E372B57D2FBB52AGeneric name
Calcium gluconateSource ID
H51-48B08E783B3AD11B100FB11CAliases
- calcium gluconate 10%
Source ID
H51-BC4FCCE1208D4B7FE3E9A889
Class
Electrolytes and fluidsSource ID
H51-E6403603B2263FE3F4EAFCE9Subclass
Calcium replacementSource ID
H51-7D34DAD141E33F03B2C27D42Summary
Calcium salt preferred over calcium chloride for many peripheral-line applications because it is less damaging with extravasation, though tissue injury remains possible.Source ID
H51-6392D4669FC38CCF1486F5B6Populations
- Adult
Source ID
H51-F37C69EB8F0D09FB6FA37A85 - Pediatric
Source ID
H51-2ED26A74649ACDFE55F142EE - Neonatal
Source ID
H51-1BE9EDB8F81B9714A0BB7C3D
Evidence tier
Core reference - verify current labelSource ID
H51-408EA05070B62DFC375057EAHigh alert
trueSource ID
H51-56AD66CC621E0435B88541F7Hazardous
falseSource ID
H51-956C05544B70C2B87371D78EStatus
ActiveSource ID
H51-C04BD3EC5D5CE1835B0FD0DDReviewed
2026-08-29Source ID
H51-77ED9671210F377BD0AE599AVersion added
1.0Source ID
H51-DCDC54FEED1A23F45821F4E7Sources
| Label | Url | Kind |
|---|---|---|
Source IDH51-8C80BC209741B2F7B48AAA76Source IDH51-4A09E65B652D30BB93D1B224 | https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Calcium+gluconate (opens in a new tab)Source IDH51-090CE9128FB54869479219A2 | PrimarySource IDH51-E080DA56F9A475D2114D724B |
Source IDH51-9B67F57C6C7DC26F8FE74D54Source IDH51-F779ECA3B7EA975211C6A1C6 | legacy:autoSource IDH51-3441FAC0162FDD252839FA6C | LegacySource IDH51-2DEE110BAD82BBEF578B088C |
Legacy title
Calcium gluconateSource ID
H51-88E6F85A1812C6CD67D8955CClinical release verification
- Audit version
- 3.4
Source ID
H51-F45D3A9AF3527588F1C6F79E - Audited on
- 2026-08-30
Source ID
H51-0EA52D6757C7FEB6A29D4DA7 - Level
- amber
Source ID
H51-FD7B1CCD90BA29989555A07C - Release gate
- trusted_professional_source_present_exact_label_unconfirmed
Source ID
H51-F3A228011B2BF3771B26D31B - Exact current label candidate
- false
Source ID
H51-2C6034ADE4FB4F8288AE0297 - Numeric support ratio
- 0
Source ID
H51-DA7C5199C7EF86826EC3D152 - Reference url count
- 1
Source ID
H51-FF82925AC1AD5A897C552813 - Broken reference count
- 0
Source ID
H51-4C130F591829E1ABA02B7ACD - Point of use confirmation required
- true
Source ID
H51-6109B997542FD4091EF91202 - Note
- Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
Source ID
H51-21DFFC60C6E68E37C1B1AF9A - Dailymed search url
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Calcium%20gluconate (opens in a new tab)
Source ID
H51-B0D86F81A86BFE1A08AB9119
Dosing source fields
Id
calcium-gluconateSource ID
H51-A14FA62D301FDF7F85628302Generic name
Calcium gluconateSource ID
H51-A80E228DDB1615CFFC7341E0Coverage status
direct_official_label_access_plus_local_snapshotSource ID
H51-6047E08441EB1D323FB0A9F4Package insert
- Query name
- Calcium gluconate
Source ID
H51-C0559CFAB506B157B0CF9438 - Product and route must match
- true
Source ID
H51-FC2D27CC5CC6CBE7E81AFB97 - Live current label enabled
- false
Source ID
H51-E69C0BA69F87571D446918F1 - Source priority
- Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
Source ID
H51-DAB51DFC9F2B1CF977E920FB - Direct official label access enabled
- true
Source ID
H51-9F1D5B213295E4BE63213CE1 - Outbound server request required
- false
Source ID
H51-BD177F68190F078347ADB5CD - Local summary status
- not_bundled
Source ID
H51-3889BA59A2FE414F19CD8625
Clinical review
- Locally normalized
- false
Source ID
H51-F00F4F9342B333C8205D157D - Reviewed
- 2026-08-29
Source ID
H51-B45E3B681F1D844A6D713DDA - Status
- Direct official package-insert access enabled; indication-specific local normalization pending.
Source ID
H51-0833FCA96AD8A32733E7A4B7
Clinical release verification
- Audit version
- 3.4
Source ID
H51-EB3BF3D45D9445C5AEFACA62 - Audited on
- 2026-08-30
Source ID
H51-DEA1D330112A59B200988F4B - Level
- amber
Source ID
H51-C2768677F3BD1DB5AF782F2E - Release gate
- trusted_professional_source_present_exact_label_unconfirmed
Source ID
H51-13BE96245CD89FEF242A5F91 - Exact current label candidate
- false
Source ID
H51-A5A08EFFCAD84A1B5C048D34 - Numeric support ratio
- 0
Source ID
H51-DB6B462027FDFA45D35FE47E - Reference url count
- 1
Source ID
H51-564E3C39EA8C78D1D283FFE8 - Broken reference count
- 0
Source ID
H51-EC72A0D0407B46AE519317DE - Point of use confirmation required
- true
Source ID
H51-9A2B271465216358D8DA3D86 - Note
- Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
Source ID
H51-11B5FBC14EAB4067C33FED76 - Dailymed search url
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Calcium%20gluconate (opens in a new tab)
Source ID
H51-E0FB0CE3CBD911BCB1644F1D
Historical preparation assessment
Recovered v5.1 source content; historical, awaiting current review.
- Id
- calcium-gluconate
Source ID
H51-7ED0A95A1A8A5B4D43180586 - Name
- Calcium gluconate
Source ID
H51-FE9CEA581072F4D9DE2797BF - Therapeutic class
- Electrolytes and fluids
Source ID
H51-EF816155BCBD6E942033974A - Review version
- 3.1
Source ID
H51-6DE640D9BCBA27C4ECDA7362 - Review date
- 2026-08-30
Source ID
H51-D14E1C2C595C02F0B671467A - Release status
- structured_record_current_label_not_confirmed
Source ID
H51-983060D5CDD80592661938CE - Market status
- Status
- no_current_us_iv_spl_confirmed
Source ID
H51-0E771D27DCA28A67F8819CA0 - Basis
- No high-confidence current IV SPL was automatically selected; legacy information is segregated
Source ID
H51-E330D75FF801AC855197FC9F
- Ten point assessment
- Exact formulation
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-E150FE7A669E60B3F382CB78 - Reconstitution concentration
- Usually supplied as 100 mg/mL solution. Use pharmacy-prepared dilution.
Source ID
H51-5BB8D91569ABCA81E6D683BE - Maximum or recommended final concentration
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-217BD563C95AE9DCEF949A81 - Appropriate standardized containers
- 50 to 100 mL for routine replacement Weight-appropriate volume
Source ID
H51-69A659EC76AA76DE376BF63B - Adult dosing range
- Common dose 1 to 2 g of 10% solution Weight-based dose Commonly 1 g of 10% solution Commonly 1 g of 10% solution
Source ID
H51-35885E8746B1E68FAD91542E - Pediatric dosing range
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-E6D76E118AA9CD295C7BA550 - Neonatal dosing range
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-E52C7097F54414A9C147CFAE - Infusion time
- Infuse over 10 to 60 minutes depending on urgency and dose Slow monitored administration Usually over approximately 10 minutes while perfusing
Source ID
H51-8A44C6A47F6596C483C7B33C - Fluid restriction alternatives
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-B844D5315DFB3ED14A113D8A - Current manufacturer labeling
- Match confidence
- unresolved
Source ID
H51-4D8C02342D44D4909E7544A6 - Url
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Calcium+gluconate (opens in a new tab)
Source ID
H51-A94F53DA66EABC190ABE3B7E
- Field provenance
- Exact formulation
- Primary
- not_found
Source ID
H51-51A4DF615CCC067980F964F5
- Reconstitution concentration
- Primary
- existing_structured_record
Source ID
H51-7A16E69CECF1E1D12218D3D9
- Maximum or recommended final concentration
- Primary
- not_found
Source ID
H51-348E0B841C480157251DF235
- Appropriate standardized containers
- Primary
- existing_structured_record
Source ID
H51-BC64B58154F02B3CA79E8EFF
- Adult dosing range
- Primary
- existing_structured_record
Source ID
H51-B1C5CD7457E22D3767C2E297
- Pediatric dosing range
- Primary
- not_found
Source ID
H51-565EAF2F24BD97E93DEEBD3E
- Neonatal dosing range
- Primary
- not_found
Source ID
H51-651F923DBC1F8582238CB5A4
- Infusion time
- Primary
- existing_structured_record
Source ID
H51-DD795E37BA3ABB47715D2871
- Fluid restriction alternatives
- Primary
- not_found
Source ID
H51-2F439C8E19E40249ADE580EA
- Current manufacturer labeling
- Primary
- DailyMed search gateway
Source ID
H51-3CDBF84C2804263DDE986DF0
- Population applicability
- Adult
- Applicability
- supported_or_source_present
Source ID
H51-D5187CDEA7B80F0A8996E807 - Guide generation allowed
- true
Source ID
H51-D6F1F01AC9666C49FE0C9DB0
- Pediatric
- Applicability
- supported_or_source_present
Source ID
H51-9EFB0611BEE5A687016CDDA4 - Guide generation allowed
- false
Source ID
H51-EA4105CE41CBDD7843B79513
- Neonatal
- Applicability
- supported_or_source_present
Source ID
H51-502CA456B44DBC27FB55E3D9 - Guide generation allowed
- false
Source ID
H51-51D05898C900C99D628D2030
- Route presence
- Structured dilution
- true
Source ID
H51-D3812B8730B9A2839D345130 - Iv push
- true
Source ID
H51-D3220CB10B739AF5E74A2F39 - Continuous infusion
- true
Source ID
H51-1C7A65BD5EA7BED0134515F4 - Pediatric source
- true
Source ID
H51-5FC26B6C6CAA6BE809DAD4FC - Neonatal source
- true
Source ID
H51-4BDDAE3DA7590D9DADD0E3BF
- Legacy reference
- Status
- not_available
Source ID
H51-7BD77A44C9AD934AEB5F1321
- Label resolution
- Status
- build_environment_network_unavailable
Source ID
H51-D6159B380B0F81B68A686E05
- Source files
- catalog.json
Source ID
H51-A79A7D6C7417F66116A64921 - dosing.json
Source ID
H51-B1B21B40C065C3EB26BC928D - legacy-map.json
Source ID
H51-DA264B90EA2978D822BF37AA
- catalog.json
- Clinical release note
- Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
Source ID
H51-06B817B18691490AFE4FB85B
Historical statement IDs and source locations
These IDs identify recovered source units. They are not evidence-qualified clinical claims.
| Historical ID | Original source location | Status |
|---|---|---|
H51-0B77ECC74E372B57D2FBB52A | catalog.json/records/38/id | Historical; current review incomplete |
H51-48B08E783B3AD11B100FB11C | catalog.json/records/38/generic_name | Historical; current review incomplete |
H51-BC4FCCE1208D4B7FE3E9A889 | catalog.json/records/38/aliases/0 | Historical; current review incomplete |
H51-E6403603B2263FE3F4EAFCE9 | catalog.json/records/38/class | Historical; current review incomplete |
H51-7D34DAD141E33F03B2C27D42 | catalog.json/records/38/subclass | Historical; current review incomplete |
H51-6392D4669FC38CCF1486F5B6 | catalog.json/records/38/summary | Historical; current review incomplete |
H51-77AE02271CB27C17B26F7636 | catalog.json/records/38/common_uses/0 | Historical; current review incomplete |
H51-A011BABB2CDCC47F184A063C | catalog.json/records/38/common_uses/1 | Historical; current review incomplete |
H51-D80D84BB2E4A714260201937 | catalog.json/records/38/common_uses/2 | Historical; current review incomplete |
H51-752B67A443626F5C1F2893D0 | catalog.json/records/38/preparations/0 | Historical; current review incomplete |
H51-FB053CE2D2711FD3DE2CE205 | catalog.json/records/38/preparations/0/population | Historical; current review incomplete |
H51-889B5CDD7C4D4F6A4263BC46 | catalog.json/records/38/preparations/0/amount | Historical; current review incomplete |
H51-89C81ADFD16C45A2CB4B065E | catalog.json/records/38/preparations/0/reconstitution | Historical; current review incomplete |
H51-AFEDE88CC768A0DA6262B435 | catalog.json/records/38/preparations/0/diluent | Historical; current review incomplete |
H51-DC3BF63EB795AD688A077E37 | catalog.json/records/38/preparations/0/final_volume | Historical; current review incomplete |
H51-68447324E43F8A031AE4CCAC | catalog.json/records/38/preparations/0/concentration | Historical; current review incomplete |
H51-B5CFE20F3FAD5BB0F023D13F | catalog.json/records/38/preparations/0/rate | Historical; current review incomplete |
H51-E6D2F4B78564B93B9F6CCA75 | catalog.json/records/38/preparations/0/stability | Historical; current review incomplete |
H51-B30A5E439AAF55D99E33A849 | catalog.json/records/38/preparations/0/notes | Historical; current review incomplete |
H51-1B5C940C0267389EC03299AE | catalog.json/records/38/preparations/1 | Historical; current review incomplete |
H51-2C20C18B2EA9D6F0ED2BCFC1 | catalog.json/records/38/preparations/1/population | Historical; current review incomplete |
H51-CB53A0DEE0224B976AC7DE3D | catalog.json/records/38/preparations/1/amount | Historical; current review incomplete |
H51-199D2A8CB4EFB145E7527DC7 | catalog.json/records/38/preparations/1/reconstitution | Historical; current review incomplete |
H51-95DBA33F8765BE5B215940D1 | catalog.json/records/38/preparations/1/diluent | Historical; current review incomplete |
H51-6FEA4EADA8DCB1B5C5BB1663 | catalog.json/records/38/preparations/1/final_volume | Historical; current review incomplete |
H51-1498FD4AB0548478C21C60C2 | catalog.json/records/38/preparations/1/concentration | Historical; current review incomplete |
H51-BE0E5485E342FF715917DB89 | catalog.json/records/38/preparations/1/rate | Historical; current review incomplete |
H51-83D2E3C56E644D009AC1A403 | catalog.json/records/38/preparations/1/stability | Historical; current review incomplete |
H51-7CFC206AD25C101A3EEFE023 | catalog.json/records/38/preparations/1/notes | Historical; current review incomplete |
H51-56211A897F6175595A2394F0 | catalog.json/records/38/iv_push/0 | Historical; current review incomplete |
H51-A2AB302526AE79C33C1EAC44 | catalog.json/records/38/iv_push/0/population | Historical; current review incomplete |
H51-684F93347BD818D8D4BAE993 | catalog.json/records/38/iv_push/0/dose_scope | Historical; current review incomplete |
H51-E9CABD6F8284690C76507FB1 | catalog.json/records/38/iv_push/0/concentration | Historical; current review incomplete |
H51-86FCB0FDFB87FDE1A94BFA2C | catalog.json/records/38/iv_push/0/rate | Historical; current review incomplete |
H51-ED6EB375EA8FD96866C8005B | catalog.json/records/38/iv_push/0/status | Historical; current review incomplete |
H51-9C1BD6D1338553106622EE8E | catalog.json/records/38/iv_push/0/notes | Historical; current review incomplete |
H51-C6F97FB0A8B425F614A5ACB2 | catalog.json/records/38/warnings/0 | Historical; current review incomplete |
H51-7DF0509F448ADB346365032C | catalog.json/records/38/warnings/1 | Historical; current review incomplete |
H51-33DF67AB9D27C846EC1E2E4E | catalog.json/records/38/warnings/2 | Historical; current review incomplete |
H51-CC776726D281464802774F75 | catalog.json/records/38/monitoring/0 | Historical; current review incomplete |
H51-0391EC0E76F629FAB5B255B2 | catalog.json/records/38/monitoring/1 | Historical; current review incomplete |
H51-78E8C82F667891C85988356C | catalog.json/records/38/monitoring/2 | Historical; current review incomplete |
H51-F37C69EB8F0D09FB6FA37A85 | catalog.json/records/38/populations/0 | Historical; current review incomplete |
H51-2ED26A74649ACDFE55F142EE | catalog.json/records/38/populations/1 | Historical; current review incomplete |
H51-1BE9EDB8F81B9714A0BB7C3D | catalog.json/records/38/populations/2 | Historical; current review incomplete |
H51-408EA05070B62DFC375057EA | catalog.json/records/38/evidence_tier | Historical; current review incomplete |
H51-56AD66CC621E0435B88541F7 | catalog.json/records/38/high_alert | Historical; current review incomplete |
H51-956C05544B70C2B87371D78E | catalog.json/records/38/hazardous | Historical; current review incomplete |
H51-C04BD3EC5D5CE1835B0FD0DD | catalog.json/records/38/status | Historical; current review incomplete |
H51-77ED9671210F377BD0AE599A | catalog.json/records/38/reviewed | Historical; current review incomplete |
H51-DCDC54FEED1A23F45821F4E7 | catalog.json/records/38/version_added | Historical; current review incomplete |
H51-8C80BC209741B2F7B48AAA76 | catalog.json/records/38/sources/0 | Historical; current review incomplete |
H51-4A09E65B652D30BB93D1B224 | catalog.json/records/38/sources/0/label | Historical; current review incomplete |
H51-090CE9128FB54869479219A2 | catalog.json/records/38/sources/0/url | Historical; current review incomplete |
H51-E080DA56F9A475D2114D724B | catalog.json/records/38/sources/0/kind | Historical; current review incomplete |
H51-9B67F57C6C7DC26F8FE74D54 | catalog.json/records/38/sources/1 | Historical; current review incomplete |
H51-F779ECA3B7EA975211C6A1C6 | catalog.json/records/38/sources/1/label | Historical; current review incomplete |
H51-3441FAC0162FDD252839FA6C | catalog.json/records/38/sources/1/url | Historical; current review incomplete |
H51-2DEE110BAD82BBEF578B088C | catalog.json/records/38/sources/1/kind | Historical; current review incomplete |
H51-88E6F85A1812C6CD67D8955C | catalog.json/records/38/legacy_title | Historical; current review incomplete |
H51-F45D3A9AF3527588F1C6F79E | catalog.json/records/38/clinical_release_verification/audit_version | Historical; current review incomplete |
H51-0EA52D6757C7FEB6A29D4DA7 | catalog.json/records/38/clinical_release_verification/audited_on | Historical; current review incomplete |
H51-FD7B1CCD90BA29989555A07C | catalog.json/records/38/clinical_release_verification/level | Historical; current review incomplete |
H51-F3A228011B2BF3771B26D31B | catalog.json/records/38/clinical_release_verification/release_gate | Historical; current review incomplete |
H51-2C6034ADE4FB4F8288AE0297 | catalog.json/records/38/clinical_release_verification/exact_current_label_candidate | Historical; current review incomplete |
H51-A4CD526D2B37CB7CBB9E7DCC | catalog.json/records/38/clinical_release_verification/selected_setid | Historical; current review incomplete |
H51-4EB25468BFFBB19DB4D27C1F | catalog.json/records/38/clinical_release_verification/selected_label_title | Historical; current review incomplete |
H51-DA7C5199C7EF86826EC3D152 | catalog.json/records/38/clinical_release_verification/numeric_support_ratio | Historical; current review incomplete |
H51-FF82925AC1AD5A897C552813 | catalog.json/records/38/clinical_release_verification/reference_url_count | Historical; current review incomplete |
H51-4C130F591829E1ABA02B7ACD | catalog.json/records/38/clinical_release_verification/broken_reference_count | Historical; current review incomplete |
H51-6109B997542FD4091EF91202 | catalog.json/records/38/clinical_release_verification/point_of_use_confirmation_required | Historical; current review incomplete |
H51-21DFFC60C6E68E37C1B1AF9A | catalog.json/records/38/clinical_release_verification/note | Historical; current review incomplete |
H51-B0D86F81A86BFE1A08AB9119 | catalog.json/records/38/clinical_release_verification/dailymed_search_url | Historical; current review incomplete |
H51-A14FA62D301FDF7F85628302 | dosing.json/records/38/id | Historical; current review incomplete |
H51-A80E228DDB1615CFFC7341E0 | dosing.json/records/38/generic_name | Historical; current review incomplete |
H51-6047E08441EB1D323FB0A9F4 | dosing.json/records/38/coverage_status | Historical; current review incomplete |
H51-C0559CFAB506B157B0CF9438 | dosing.json/records/38/package_insert/query_name | Historical; current review incomplete |
H51-1C704691DB434AC2439FC3FB | dosing.json/records/38/package_insert/preferred_setid | Historical; current review incomplete |
H51-FC2D27CC5CC6CBE7E81AFB97 | dosing.json/records/38/package_insert/product_and_route_must_match | Historical; current review incomplete |
H51-E69C0BA69F87571D446918F1 | dosing.json/records/38/package_insert/live_current_label_enabled | Historical; current review incomplete |
H51-DAB51DFC9F2B1CF977E920FB | dosing.json/records/38/package_insert/source_priority | Historical; current review incomplete |
H51-9F1D5B213295E4BE63213CE1 | dosing.json/records/38/package_insert/direct_official_label_access_enabled | Historical; current review incomplete |
H51-BD177F68190F078347ADB5CD | dosing.json/records/38/package_insert/outbound_server_request_required | Historical; current review incomplete |
H51-3889BA59A2FE414F19CD8625 | dosing.json/records/38/package_insert/local_summary_status | Historical; current review incomplete |
H51-80295CBD8DB0B71177C9C1F4 | dosing.json/records/38/renal/classification | Historical; current review incomplete |
H51-E0757F1AD49037951B277605 | dosing.json/records/38/renal/summary | Historical; current review incomplete |
H51-145E2C382E1240CD559E5657 | dosing.json/records/38/renal/method_note | Historical; current review incomplete |
H51-D16D18944A0473283DF011CF | dosing.json/records/38/existing_route_snapshots/0 | Historical; current review incomplete |
H51-D226F3C585313B94337057B6 | dosing.json/records/38/existing_route_snapshots/0/route | Historical; current review incomplete |
H51-BFEFDA5E51F413357EBB18E5 | dosing.json/records/38/existing_route_snapshots/0/population | Historical; current review incomplete |
H51-2A5FA07D25FD68D74C553FF8 | dosing.json/records/38/existing_route_snapshots/0/indication | Historical; current review incomplete |
H51-9BBB03B67199EF800FEEDA77 | dosing.json/records/38/existing_route_snapshots/0/dose | Historical; current review incomplete |
H51-FFD5CA9FDF7CB88D372F5EF7 | dosing.json/records/38/existing_route_snapshots/0/interval | Historical; current review incomplete |
H51-111D0032481D85C4454AD5F1 | dosing.json/records/38/existing_route_snapshots/0/duration | Historical; current review incomplete |
H51-B23C10D340A46A0C808346DE | dosing.json/records/38/existing_route_snapshots/0/administration | Historical; current review incomplete |
H51-DAAC23FBBB8BB4D5B335499C | dosing.json/records/38/existing_route_snapshots/0/source_level | Historical; current review incomplete |
H51-AED54F0BCCD41BF77CE46248 | dosing.json/records/38/existing_route_snapshots/0/notes | Historical; current review incomplete |
H51-39322B30B56D14E3B877CA6D | dosing.json/records/38/existing_route_snapshots/1 | Historical; current review incomplete |
H51-33BB04B913CCB4625C524181 | dosing.json/records/38/existing_route_snapshots/1/route | Historical; current review incomplete |
H51-4DD2ABE38F2AD2F2E87FAA03 | dosing.json/records/38/existing_route_snapshots/1/population | Historical; current review incomplete |
H51-12903A53641A5154ABB3676C | dosing.json/records/38/existing_route_snapshots/1/indication | Historical; current review incomplete |
H51-50F303815513C856A3D62CF6 | dosing.json/records/38/existing_route_snapshots/1/dose | Historical; current review incomplete |
H51-7F50993576AC5C73501BACD9 | dosing.json/records/38/existing_route_snapshots/1/interval | Historical; current review incomplete |
H51-594CD14D75B68A158F1B1D35 | dosing.json/records/38/existing_route_snapshots/1/duration | Historical; current review incomplete |
H51-D07048378CFD245F8B8AC0F6 | dosing.json/records/38/existing_route_snapshots/1/administration | Historical; current review incomplete |
H51-A7C53403A8D3348C0C1AFF9C | dosing.json/records/38/existing_route_snapshots/1/source_level | Historical; current review incomplete |
H51-B63C6032EC5E5F9E2EFC3136 | dosing.json/records/38/existing_route_snapshots/1/notes | Historical; current review incomplete |
H51-8DD153F9710F0F5459BBDBAF | dosing.json/records/38/existing_route_snapshots/2 | Historical; current review incomplete |
H51-C5C9E73A4CDA4DA1BD3F3626 | dosing.json/records/38/existing_route_snapshots/2/route | Historical; current review incomplete |
H51-69EBB4D296621642E518C983 | dosing.json/records/38/existing_route_snapshots/2/population | Historical; current review incomplete |
H51-D00ABF74FC2E18CB59FEAAB3 | dosing.json/records/38/existing_route_snapshots/2/indication | Historical; current review incomplete |
H51-BB1F4EBD3654D4E3C0C3FB8F | dosing.json/records/38/existing_route_snapshots/2/dose | Historical; current review incomplete |
H51-10CA5B94042DA1C4B338CF9A | dosing.json/records/38/existing_route_snapshots/2/interval | Historical; current review incomplete |
H51-ED5872DAF1571A648B7BFA14 | dosing.json/records/38/existing_route_snapshots/2/duration | Historical; current review incomplete |
H51-19319F212AF56EBD3E01C899 | dosing.json/records/38/existing_route_snapshots/2/administration | Historical; current review incomplete |
H51-1A159382BF5DF9FA22A986DA | dosing.json/records/38/existing_route_snapshots/2/source_level | Historical; current review incomplete |
H51-34433989BB37032D64630286 | dosing.json/records/38/existing_route_snapshots/2/notes | Historical; current review incomplete |
H51-F00F4F9342B333C8205D157D | dosing.json/records/38/clinical_review/locally_normalized | Historical; current review incomplete |
H51-B45E3B681F1D844A6D713DDA | dosing.json/records/38/clinical_review/reviewed | Historical; current review incomplete |
H51-0833FCA96AD8A32733E7A4B7 | dosing.json/records/38/clinical_review/status | Historical; current review incomplete |
H51-EB3BF3D45D9445C5AEFACA62 | dosing.json/records/38/clinical_release_verification/audit_version | Historical; current review incomplete |
H51-DEA1D330112A59B200988F4B | dosing.json/records/38/clinical_release_verification/audited_on | Historical; current review incomplete |
H51-C2768677F3BD1DB5AF782F2E | dosing.json/records/38/clinical_release_verification/level | Historical; current review incomplete |
H51-13BE96245CD89FEF242A5F91 | dosing.json/records/38/clinical_release_verification/release_gate | Historical; current review incomplete |
H51-A5A08EFFCAD84A1B5C048D34 | dosing.json/records/38/clinical_release_verification/exact_current_label_candidate | Historical; current review incomplete |
H51-74ADCC3A5E3560BC2C898ECE | dosing.json/records/38/clinical_release_verification/selected_setid | Historical; current review incomplete |
H51-5E3486CF36C8471D893C9C5C | dosing.json/records/38/clinical_release_verification/selected_label_title | Historical; current review incomplete |
H51-DB6B462027FDFA45D35FE47E | dosing.json/records/38/clinical_release_verification/numeric_support_ratio | Historical; current review incomplete |
H51-564E3C39EA8C78D1D283FFE8 | dosing.json/records/38/clinical_release_verification/reference_url_count | Historical; current review incomplete |
H51-EC72A0D0407B46AE519317DE | dosing.json/records/38/clinical_release_verification/broken_reference_count | Historical; current review incomplete |
H51-9A2B271465216358D8DA3D86 | dosing.json/records/38/clinical_release_verification/point_of_use_confirmation_required | Historical; current review incomplete |
H51-11B5FBC14EAB4067C33FED76 | dosing.json/records/38/clinical_release_verification/note | Historical; current review incomplete |
H51-E0FB0CE3CBD911BCB1644F1D | dosing.json/records/38/clinical_release_verification/dailymed_search_url | Historical; current review incomplete |
H51-3A305A9ED9CE3227633E45AA | first-look-v5.1.json/records/38/id | Historical; current review incomplete |
H51-A6B682C9FBEBF4F4D16AF656 | first-look-v5.1.json/records/38/generic_name | Historical; current review incomplete |
H51-528E3CE6EB4AB0BC759A5E92 | first-look-v5.1.json/records/38/class | Historical; current review incomplete |
H51-B336C84EEC81AB6B7E51148F | first-look-v5.1.json/records/38/subclass | Historical; current review incomplete |
H51-15A7DA97D9610B798D65C067 | first-look-v5.1.json/records/38/primary_uses/0 | Historical; current review incomplete |
H51-363938626FC01E70EA255CC0 | first-look-v5.1.json/records/38/primary_uses/1 | Historical; current review incomplete |
H51-AD95CF9175CDBDE69444EB7B | first-look-v5.1.json/records/38/primary_uses/2 | Historical; current review incomplete |
H51-FD4E25B94EBF047770CDD872 | first-look-v5.1.json/records/38/mechanism | Historical; current review incomplete |
H51-11D9BA5EE15FFDA5C878D82F | first-look-v5.1.json/records/38/mechanism_level | Historical; current review incomplete |
H51-71BE40FEB968F8B181962237 | first-look-v5.1.json/records/38/basic_dosing_orientation | Historical; current review incomplete |
H51-7CAD93A8254D18DAE9B3DB2D | first-look-v5.1.json/records/38/administration_orientation | Historical; current review incomplete |
H51-8B14B55F017469153989EA30 | first-look-v5.1.json/records/38/renal_and_population_orientation | Historical; current review incomplete |
H51-3580864E16FB0D14109AB853 | first-look-v5.1.json/records/38/key_safety_orientation/0 | Historical; current review incomplete |
H51-F3AB8EA0D75BF5FFD05A7C98 | first-look-v5.1.json/records/38/key_safety_orientation/1 | Historical; current review incomplete |
H51-1C61A1C1081F29FEBA10FF3F | first-look-v5.1.json/records/38/key_safety_orientation/2 | Historical; current review incomplete |
H51-BA42AF6917DF4D3E9059AA57 | first-look-v5.1.json/records/38/coverage_path | Historical; current review incomplete |
H51-0E4A17169D7FAE3B168DCF4E | first-look-v5.1.json/records/38/coverage_path_label | Historical; current review incomplete |
H51-2647F031556ED4527F41C7DC | first-look-v5.1.json/records/38/official_label_url | Historical; current review incomplete |
H51-6E0C550FCD57FAED7806CDDB | first-look-v5.1.json/records/38/legacy_title | Historical; current review incomplete |
H51-0579C62220ACC80BAB01ECC7 | first-look-v5.1.json/records/38/review_note | Historical; current review incomplete |
H51-A96D5AA933DB577CC769F22B | first-look-v5.1.json/records/38/search_text | Historical; current review incomplete |
H51-D2A988BCE82934A449055C13 | first-look-v5.1.json/records/38/official_search_url | Historical; current review incomplete |
H51-E65AF12ADC139FCC63FFEC5B | first-look-v5.1.json/records/38/official_access_mode | Historical; current review incomplete |
H51-9AFA308CE86D023F004BFCA8 | first-look-v5.1.json/records/38/official_access_url | Historical; current review incomplete |
H51-4A3C37830387524DA5AA3B0B | first-look-v5.1.json/records/38/official_search_query | Historical; current review incomplete |
H51-2E139A751E58F87716D26956 | first-look-v5.1.json/records/38/official_access_reason | Historical; current review incomplete |
H51-7ED0A95A1A8A5B4D43180586 | preparation-assessments-v3.8.json/38/id | Historical; current review incomplete |
H51-FE9CEA581072F4D9DE2797BF | preparation-assessments-v3.8.json/38/name | Historical; current review incomplete |
H51-4A8C6B16F21FDE2F95876E20 | preparation-assessments-v3.8.json/38/brands | Historical; current review incomplete |
H51-EF816155BCBD6E942033974A | preparation-assessments-v3.8.json/38/therapeutic_class | Historical; current review incomplete |
H51-6DE640D9BCBA27C4ECDA7362 | preparation-assessments-v3.8.json/38/review_version | Historical; current review incomplete |
H51-D14E1C2C595C02F0B671467A | preparation-assessments-v3.8.json/38/review_date | Historical; current review incomplete |
H51-983060D5CDD80592661938CE | preparation-assessments-v3.8.json/38/release_status | Historical; current review incomplete |
H51-0E771D27DCA28A67F8819CA0 | preparation-assessments-v3.8.json/38/market_status/status | Historical; current review incomplete |
H51-E330D75FF801AC855197FC9F | preparation-assessments-v3.8.json/38/market_status/basis | Historical; current review incomplete |
H51-E150FE7A669E60B3F382CB78 | preparation-assessments-v3.8.json/38/ten_point_assessment/exact_formulation | Historical; current review incomplete |
H51-5BB8D91569ABCA81E6D683BE | preparation-assessments-v3.8.json/38/ten_point_assessment/reconstitution_concentration | Historical; current review incomplete |
H51-217BD563C95AE9DCEF949A81 | preparation-assessments-v3.8.json/38/ten_point_assessment/maximum_or_recommended_final_concentration | Historical; current review incomplete |
H51-69A659EC76AA76DE376BF63B | preparation-assessments-v3.8.json/38/ten_point_assessment/appropriate_standardized_containers | Historical; current review incomplete |
H51-35885E8746B1E68FAD91542E | preparation-assessments-v3.8.json/38/ten_point_assessment/adult_dosing_range | Historical; current review incomplete |
H51-E6D76E118AA9CD295C7BA550 | preparation-assessments-v3.8.json/38/ten_point_assessment/pediatric_dosing_range | Historical; current review incomplete |
H51-E52C7097F54414A9C147CFAE | preparation-assessments-v3.8.json/38/ten_point_assessment/neonatal_dosing_range | Historical; current review incomplete |
H51-8A44C6A47F6596C483C7B33C | preparation-assessments-v3.8.json/38/ten_point_assessment/infusion_time | Historical; current review incomplete |
H51-B844D5315DFB3ED14A113D8A | preparation-assessments-v3.8.json/38/ten_point_assessment/fluid_restriction_alternatives | Historical; current review incomplete |
H51-ED293752D88F110D5589917B | preparation-assessments-v3.8.json/38/ten_point_assessment/current_manufacturer_labeling/setid | Historical; current review incomplete |
H51-B10C14E4DE531F7C940D4CC8 | preparation-assessments-v3.8.json/38/ten_point_assessment/current_manufacturer_labeling/title | Historical; current review incomplete |
H51-AAFB89766C0543D43300BCA6 | preparation-assessments-v3.8.json/38/ten_point_assessment/current_manufacturer_labeling/published_date | Historical; current review incomplete |
H51-402F6B518D61FEE8E1EA5C9A | preparation-assessments-v3.8.json/38/ten_point_assessment/current_manufacturer_labeling/manufacturer | Historical; current review incomplete |
H51-4D8C02342D44D4909E7544A6 | preparation-assessments-v3.8.json/38/ten_point_assessment/current_manufacturer_labeling/match_confidence | Historical; current review incomplete |
H51-A94F53DA66EABC190ABE3B7E | preparation-assessments-v3.8.json/38/ten_point_assessment/current_manufacturer_labeling/url | Historical; current review incomplete |
H51-51A4DF615CCC067980F964F5 | preparation-assessments-v3.8.json/38/field_provenance/exact_formulation/primary | Historical; current review incomplete |
H51-7A16E69CECF1E1D12218D3D9 | preparation-assessments-v3.8.json/38/field_provenance/reconstitution_concentration/primary | Historical; current review incomplete |
H51-348E0B841C480157251DF235 | preparation-assessments-v3.8.json/38/field_provenance/maximum_or_recommended_final_concentration/primary | Historical; current review incomplete |
H51-BC64B58154F02B3CA79E8EFF | preparation-assessments-v3.8.json/38/field_provenance/appropriate_standardized_containers/primary | Historical; current review incomplete |
H51-B1C5CD7457E22D3767C2E297 | preparation-assessments-v3.8.json/38/field_provenance/adult_dosing_range/primary | Historical; current review incomplete |
H51-565EAF2F24BD97E93DEEBD3E | preparation-assessments-v3.8.json/38/field_provenance/pediatric_dosing_range/primary | Historical; current review incomplete |
H51-651F923DBC1F8582238CB5A4 | preparation-assessments-v3.8.json/38/field_provenance/neonatal_dosing_range/primary | Historical; current review incomplete |
H51-DD795E37BA3ABB47715D2871 | preparation-assessments-v3.8.json/38/field_provenance/infusion_time/primary | Historical; current review incomplete |
H51-2F439C8E19E40249ADE580EA | preparation-assessments-v3.8.json/38/field_provenance/fluid_restriction_alternatives/primary | Historical; current review incomplete |
H51-3CDBF84C2804263DDE986DF0 | preparation-assessments-v3.8.json/38/field_provenance/current_manufacturer_labeling/primary | Historical; current review incomplete |
H51-D5187CDEA7B80F0A8996E807 | preparation-assessments-v3.8.json/38/population_applicability/adult/applicability | Historical; current review incomplete |
H51-D6F1F01AC9666C49FE0C9DB0 | preparation-assessments-v3.8.json/38/population_applicability/adult/guide_generation_allowed | Historical; current review incomplete |
H51-9EFB0611BEE5A687016CDDA4 | preparation-assessments-v3.8.json/38/population_applicability/pediatric/applicability | Historical; current review incomplete |
H51-EA4105CE41CBDD7843B79513 | preparation-assessments-v3.8.json/38/population_applicability/pediatric/guide_generation_allowed | Historical; current review incomplete |
H51-502CA456B44DBC27FB55E3D9 | preparation-assessments-v3.8.json/38/population_applicability/neonatal/applicability | Historical; current review incomplete |
H51-51D05898C900C99D628D2030 | preparation-assessments-v3.8.json/38/population_applicability/neonatal/guide_generation_allowed | Historical; current review incomplete |
H51-D3812B8730B9A2839D345130 | preparation-assessments-v3.8.json/38/route_presence/structured_dilution | Historical; current review incomplete |
H51-D3220CB10B739AF5E74A2F39 | preparation-assessments-v3.8.json/38/route_presence/iv_push | Historical; current review incomplete |
H51-1C7A65BD5EA7BED0134515F4 | preparation-assessments-v3.8.json/38/route_presence/continuous_infusion | Historical; current review incomplete |
H51-5FC26B6C6CAA6BE809DAD4FC | preparation-assessments-v3.8.json/38/route_presence/pediatric_source | Historical; current review incomplete |
H51-4BDDAE3DA7590D9DADD0E3BF | preparation-assessments-v3.8.json/38/route_presence/neonatal_source | Historical; current review incomplete |
H51-7BD77A44C9AD934AEB5F1321 | preparation-assessments-v3.8.json/38/legacy_reference/status | Historical; current review incomplete |
H51-D6159B380B0F81B68A686E05 | preparation-assessments-v3.8.json/38/label_resolution/status | Historical; current review incomplete |
H51-A79A7D6C7417F66116A64921 | preparation-assessments-v3.8.json/38/source_files/0 | Historical; current review incomplete |
H51-B1B21B40C065C3EB26BC928D | preparation-assessments-v3.8.json/38/source_files/1 | Historical; current review incomplete |
H51-DA264B90EA2978D822BF37AA | preparation-assessments-v3.8.json/38/source_files/2 | Historical; current review incomplete |
H51-06B817B18691490AFE4FB85B | preparation-assessments-v3.8.json/38/clinical_release_note | Historical; current review incomplete |
Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)